SHMT2 and cancer: Overall, these findings suggest that, while partially maintaining its capacity to inhibit mitochondrial OXPHOS activity, metformin loses its cytotoxic and antiproliferative activity in SHMT2-null cancer cells unable to produce energy-rich NADH or FADH2 molecules from TCA cycle substrates.